Environmental, Social And Governance Report

Overview

The report describes Hua Medicine's first full-year commercialization of HuaTangNing under China's National Reimbursement Drug List, with 2024 sales revenue rising 234% to RMB255.9 million. The company completed the Phase 1a U.S. clinical study of its second-generation GKA and advanced additional diabetes research and formulations. It also established an ESG governance structure comprising the Board of Directors, compliance committee, and ESG working group. Environmental and safety initiatives included energy-saving renovations, hazardous-waste controls, and no work-related employee fatalities during the period.

Document

Report type: Sustainability Report
Class: Dedicated
Scope: Full report
Fiscal year: 2024
Period: 1 January 2024 – 31 December 2024
Language: English
Pages
File size
Restatement: Disclosed

Reporting standards, commitments and assurance details are available with a free account.

Standards

GRI
SASB
TCFD
ISSB
ESRS
Integrated Reporting Framework
GHG Protocol
EU Taxonomy
CDP
Other

Materiality

Assessment
Basis

Assurance

Statement included

Data Services

Turn sustainability reports into a dataset built for your research.

From bulk PDFs to structured indicators and machine-readable documents.

View services